A research team in the Department of Pharmacology and Pharmacy at the LKS Faculty of Medicine of the University of Hong Kong ...

Good morning, ladies and gentlemen, and welcome to aTyr Pharma conference call to review the top line results for the Phase III EFZO-FIT study of efzofitimod in pulmonary sarcoidosis. [Operator ...

Content by Health System. With Asthma Peak Week typically during the middle of September, now is a great time to learn the ...

ATyr Pharma's stock dips after Phase 3 trial of efzofitimod misses steroid reduction goal, but shows improvements in lung function and steroid withdrawal rates.

The BeLPT has high specificity for identifying chronic beryllium disease but poor sensitivity in distinguishing it from sarcoidosis.

Study did not meet primary endpoint in change from baseline in mean daily oral corticosteroid (OCS) dose at week 48, although clinical benefit ...

Tyr Pharma (ATYR) announced topline results from the Phase 3 EFZO-FIT study of efzofitimod in 268 patients with pulmonary sarcoidosis, a major ...

A recent study reveals that COPD, or Smokers' Disease, is impacting younger individuals. Doctors in Delhi are observing a ...

Pulmonary endarterectomy surgery may more effectively improve pulmonary circulation and heart function for CTEPH than BPA, a ...

Each year, 500 to 1,000 people in the United States are diagnosed with pulmonary arterial hypertension (PAH), a rare lung ...

University of Colorado Cancer Center member D. Ross Camidge, MD, PhD, has spent his career fighting lung cancer. In 2022, ...

Corvista Health’s point-of-care device can detect cases of PH that other testing methods miss, according to a recent case ...